Relmada Therapeutics Inc Stock Ownership - Who owns Relmada Therapeutics?

Insider buying vs selling

Have Relmada Therapeutics Inc insiders been buying or selling?
Sergio TraversaChief Executive Officer2024-01-3127,460$4.00
Maged ShenoudaChief Financial Officer2024-01-316,875$4.06
Chuck EnceCA and CO2024-01-3113,670$4.06
Maged ShenoudaChief Financial Officer2024-01-3015,000$3.89
Chuck EnceCA and CO2024-01-3014,500$3.87
Sergio TraversaChief Executive Officer2024-01-3040,999$3.90
Sergio TraversaChief Executive Officer2024-01-2931,541$3.71
Maged ShenoudaChief Financial Officer2024-01-2910,800$3.65
Chuck EnceCA and CO2024-01-2910,800$3.65

1 of 1

RLMD insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when RLMD insiders and whales buy or sell their stock.

RLMD Shareholders

What type of owners hold Relmada Therapeutics Inc stock?
Vanguard Group Inc4.16%1,256,705$3.91MInstitution
Deep Track Capital LP4.11%1,240,034$3.86MInstitution
Vestal Point Capital LP3.98%1,200,000$3.73MInstitution
Acadian Asset Management LLC3.91%1,181,186$3.67MInstitution
Parsons Capital Management Inc3.23%973,520$3.03MInstitution
Opaleye Management Inc2.52%759,000$2.36MInstitution
Palo Alto Investors LP2.43%732,400$2.28MInstitution
Franklin Resources Inc2.09%630,251$1.96MInstitution
Blackrock Inc1.92%578,188$1.80MInstitution
Millennium Management LLC1.13%341,450$1.06MInstitution

1 of 3

RLMD vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RLMD47.42%3.43%Net Buying
VANI4.37%95.63%Net Buying
PLX6.49%93.51%Net Buying

Relmada Therapeutics Stock Ownership FAQ

Who owns Relmada Therapeutics?

Relmada Therapeutics (NASDAQ: RLMD) is owned by 47.42% institutional shareholders, 3.43% Relmada Therapeutics insiders, and 49.15% retail investors. Sergio Traversa is the largest individual Relmada Therapeutics shareholder, owning 244,024.00 shares representing 0.81% of the company. Sergio Traversa's Relmada Therapeutics shares are currently valued at $744.27k.

If you're new to stock investing, here's how to buy Relmada Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.